Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Many patients learn they could have cancer in the emergency department

2.

ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types

3.

EMA OKs Two Treatments for Small Cell Lung Cancer

4.

Cancer "Tidal Wave" Prediction: Not Cigarette-Based, Either! Wary Stories Regarding Cannabis and Cancer.

5.

Temsirolimus Plus Chemotherapy Fails in Rare Childhood Cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot